Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 3

Interventions

rozanolixizumab 11efgartigimod alfa 10zilucoplan 8Prednisone 8Cyclophosphamide 8ravulizumab 7Rituximab 7Pyridostigmine Bromide 7telitacicept 6fludarabine 6Tacrolimus 6Mycophenolic Acid 6eculizumab 5Immunoglobulins, Intravenous 5Hizentra 4Azathioprine 4Steroids 3HBM9161 3Data Collection 3Amifampridine 3thymoglobulin 2inebilizumab 2Thymectomy 2Prednisolone 2Methylprednisolone 2Methotrexate 2Exercise 2Diagnostic Self Evaluation 2Blood Specimen Collection 2tofacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Myasthenia Gravis × HBM9161 × Clear all
NCT05332210 2026-04-28

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
111 enrolled

Myasthenia Gravis

NCT04346888 2023-03-08

A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 2 Completed
30 enrolled

Myasthenia Gravis

NCT05039190 2023-03-08

MG

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
132 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡